Aims: To determine the accuracy of the forced expiratory volume ratio at one and six seconds (FEV1/FEV6) using a hand-held, expiratory flow meter (PiKo-6 ® , nSpire Health, Inc.) to screen for chronic obstructive pulmonary disease (COPD) in primary care settings. Conclusions: The PiKo-6 ® allows simple and reliable screening for COPD which could optimise early referral for spirometry and early, targeted interventions for COPD.
Introduction
Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality worldwide, 1 ,2 yet is typically not diagnosed until its advanced stages, causing a considerable burden to patients and health care resources. 3 Early case identification may enable better use of effective management interventions and hence a reduced disease burden. 4 However, it is accepted that the onset of COPD is insidious, leading to underdiagnosis and misdiagnosis. [5] [6] [7] [8] [9] [10] [11] [12] There have been calls for greater awareness of COPD among primary care practitioners so that diagnosis is not delayed and patients can receive early and appropriate interventions. 13 Among the tools currently available to primary care practitioners, spirometry is recognised as the 'gold standard' diagnostic test to demonstrate fixed airway obstruction. 14, 15 However, spirometry is underutilised in clinical practice 16, 17 as many practitioners do not own a spirometer, undergo little training, or lack confidence in its use or in the interpretation of results. [18] [19] [20] [21] Symptom-based questionnaires may help practitioners identify individuals with COPD in at-risk populations. 22 However, the time required to conduct and analyse these questionnaires 23 may limit their usefulness in a busy primary care practice. Therefore, in contrast to the diagnosis of hypertension, simple and reliable tools have not been readily available for primary care practitioners to diagnose COPD during routine surgery visits.
In this study we sought to develop a simple yet reliable and practical solution to COPD screening within the busy workload in primary care. We projected that if our aims were realised, such an approach would achieve greater implementation than traditional spirometry initiatives. Forced expiratory volume at six seconds of exhalation (FEV 6) is emerging as a valid alternative to forced vital capacity (FVC) for detection of COPD. [24] [25] [26] [27] Simple hand-held expiratory flow meters such as the PiKo-6 ® (nSpire Health, Inc. Longmont, CO, USA [formerly Ferraris Respiratory; Louisville, CO, USA]), that measure FEV at one and six seconds of exhalation as well as the FEV 1/FEV6 ratio, potentially provide a practical method for early screening for COPD in at-risk patient populations. 26 The current study examined the diagnostic accuracy of FEV 1 /FEV 6 using the PiKo-6 ® compared with postbronchodilator (BD) FEV 1/FVC spirometry conducted by trained operators using the Global Initiative for Chronic Obstructive Lung Disease (GOLD) spirometry COPD criteria 14 in at-risk patients in a primary care setting. In addition, the diagnostic accuracy of the ® was compared with symptom-based COPD diagnostic questionnaires that have been validated in primary care settings. 22, 23, 28 
Methods

Study design
This prospective, multicentre validation study was conducted between August and December 2006, was approved by the Royal Australian College of General Practitioners National Research and Evaluation Ethics Committee, and was undertaken in accordance with the Declaration of Helsinki and Australian regulatory requirements. Subjects were recruited from four Australian primary care practices during routine practice visits, by invitation to prescheduled study days, or through a local newspaper advertisement (one site). Two screening tests (FEV 1/FEV6 measured using the PiKo-6 ® and one of two diagnostic questionnaires) were compared with the GOLD reference criteria for COPD, based on post-BD spirometry. 14 
Study groups
Subjects were grouped into a case finding (CF) or a differential diagnosis (DD) group. Case finding group inclusion criteria were current or former smokers aged > 50 years, no previous diagnosis of obstructive lung disease (including COPD, chronic bronchitis, emphysema and/or asthma), and no treatment for obstructive lung disease in the past year. Differential diagnosis group inclusion criteria were current and former smokers aged > 50 years, a previous diagnosis of or treatment for asthma, and no previous diagnosis of COPD. Treatment for obstructive lung disease or asthma included use of inhaled or oral bronchodilators, corticosteroids, theophyllines or leukotriene inhibitors in the past year.
Exclusion criteria for both groups were refusal or inability to give consent, pre-existing or concomitant non-obstructive lung disease, symptoms suggestive of unstable heart disease, and contraindications to spirometry.
Study procedures
All tests were undertaken in a primary care setting and, with the exception of three subjects, were conducted on the same day. The test sequence comprised (i) a COPD diagnostic questionnaire (ii) measurement of pre-BD FEV1/FEV6 using the PiKo-6 ® , and (iii) pre-and post-BD spirometry. Adverse events were reported at each visit.
Questionnaires
The COPD Diagnosis Questionnaire (CDQ) and the Differential Diagnosis Questionnaire (DDQ) were administered to the CF group and DD group, respectively (see Appendix 1, available at www.thepcrj.org). Development of these questionnaires for use in primary practice has been described previously. 22, 23, 28 Hand-held expiratory flow meter (PiKo-6 ® ) FEV1, FEV6 and the calculated ratio were measured to two decimal places. Each study nurse or general practitioner (GP) was given uniform, brief training on how to use the device according to the manufacturer's instructions. Subjects were required to inhale maximally, and then exhale as hard as possible into the mouthpiece for at least six seconds until an end-of-blow beep was heard. At least three reproducible measurements (FEV 1 within 0.2 L) were taken. The measurement of acceptable quality with the highest summed value (FEV 1 + FEV6) was used.
Spirometry
Spirometry testing with bronchodilator reversibility was performed independently by trained operators according to American Thoracic Society / European Respiratory Society guidelines. 29 14 spirometry criteria. The reference criterion for COPD was a post-BD FEV 1/FVC of < 0.70, which is consistent with the diagnosis used during development and validation of the COPD diagnostic questionnaires 22, 28 and with reversibility < 200 mL and < 12% from baseline pre-BD FEV1. The post-BD FEV1 percentage of predicted values was calculated 30 and the severity of COPD classified according to GOLD definitions.
Analysis
The sample size was chosen to yield a precision (width of 95% confidence interval [CI] ) between ± 5% and ± 18% for the standard validation statistics. A small intra-cluster correlation was assumed (0.05) to account for multiple subjects per GP. Assuming a dropout rate of 15%, a sample size of 300 subjects was chosen to yield 255 subjects (165 in CF; 90 in DD). The underlying prevalence of undiagnosed COPD in each group (18% for CF; 50% for DD) was based on age-scaled Australian data (R. Attewell; unpublished data). Spirometry data were checked at 50% enrolment to confirm the prevalence of COPD in each group; no interim analyses of the device data or COPD diagnostic questionnaires were undertaken.
Questionnaires were scored by the study programmer at the completion of the trial according to the standard scoring algorithms. For each questionnaire, subjects were classified on their summed score into one of three categories (increased, intermediate or decreased likelihood of airways obstruction). 23 Diagnostic accuracies of the PiKo-6 ® FEV1/FEV6 and COPD diagnostic questionnaires were summarised by calculating the area under the receiver operating characteristic (ROC) curve (ROCAUC; roctab procedure; STATA v9, StataCorp, TX, USA) and the kappa statistic for agreement between classifications. Standard validation measures, including sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and likelihood ratio (for a positive test), were calculated at predefined cut-off points for the COPD diagnostic questionnaires 23 and at FEV 1/FEV6 ratios of < 0.66, < 0.70, < 0.75 and < 0.80 for device measurements. Calculations were undertaken with and without adjustment for clustering by each centre using the Generalised Estimating Equation approach (STATA v9). A comparison of pre-BD FEV 1/FEV6 measured using the device and spirometer was conducted using a two-sided, paired t-test. Differences were considered statistically significant at P < 0.05.
Results
Study groups
A total of 333 subjects were enrolled (see Figure 1 ). Following early review of spirometry, one site was closed because of poor compliance with the spirometry protocol. Valid spirometry and simple flow meter data were obtained from a total of 297 eligible subjects. Of these, four failed to complete the questionnaires (DD group = 1, CF group = 3).
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Of the 204 eligible subjects in the CF group, 28% (57/204) had a spirometry post-BD FEV 1/FVC < 0.70 ratio, and were assigned a study diagnosis of COPD ( Figure 1 ). Within the DD group, 39% (36/93) of subjects had spirometry-confirmed COPD. Most subjects (DD group = 81%, 29/36; CF group = 95%, 54/57) with a new diagnosis of COPD were classified as either 'mild' (FEV 1 > 80% predicted) or 'moderate' (50% ≤ FEV1 < 80% predicted) in severity on the basis of post-BD FEV 1 (Figure 1 ).
Reversible airflow limitation, consistent with asthma, was observed in 3% (6/204) of subjects in the CF group and 8% (7/93) of subjects in the DD group (Figure 1 ). In the DD group, 30% (28/93) of subjects were taking oral or inhaled corticosteroids at the time of the study, 20% (19/93) used bronchodilators before the flow meter measurements, and 27% (25/93) used bronchodilators before spirometry.
Mean age and body mass index were similar between each group, and the proportion of males and current smokers was slightly higher in the CF group than the DD group (see Table 1 ).
Diagnostic accuracy of the PiKo-6 ®
The validation estimates across cut-off points were similar between the CF groups ( Table 2 ). As the cut-off point was lowered, FEV 1/FEV6 became less sensitive but more specific, the PPV increased, the NPV decreased, and the likelihood ratio of a positive test increased. For both groups, a cut-off point corresponding to FEV 1/FEV6 < 0.75 offered optimal sensitivity (CF group = 81%; DD group = 86%) and specificity (CF group = 71%; DD group = 67%). Estimates did not differ by more than one percentage point when adjustment for clustering by device operator was incorporated into the calculations; however, the intra-cluster correlations varied in the positive and negative ranges (data not shown).
The diagnostic accuracy of the PiKo-6 ® FEV1/FEV6 in discriminating between subjects with and without COPD (as summarised by the ROCAUC value) was 0.85 (95% CI 0.79, 0.90) for the CF group and 0.88 (95% CI 0.80, 0.96) for the DD group (Figure 2) .
The diagnostic performance at the optimum FEV 1/FEV6 cutoff (< 0.75) by COPD severity is illustrated in Figure 3 . The low PPV estimates (52% and 62% for the CF and DD groups, respectively) were due to the proportion of subjects without COPD who recorded 'false positive' FEV 1/FEV6 ratios between 0.6 and 0.74. The high NPV estimates (CF group = 91%; DD group = 88%) resulted from relatively few subjects recording 'false negative' results ( Figure 3 ). All subjects who blew a false negative result had either mild or moderate COPD, and all subjects with severe or very severe COPD recorded an FEV 1/FEV6 ratio ≤ 0.6.
There were no statistically significant differences between the mean FEV 1/FEV6 determined using the simple flow meter or the spirometer. Mean pre-BD FEV 1/FEV6 for the CF group were 0.754 (simple flow meter) and 0.762 (spirometer), P = 0.14. The corresponding values for the DD group were 0.717 (simple flow meter) and 0.721 (spirometer), P = 0.64.
Few adverse events were reported. There was one case each of dizziness, chest pain and shortness of breath.
Diagnostic accuracy of the COPD diagnostic questionnaires
The diagnostic accuracy of the questionnaires was lower than the PiKo-6 ® FEV 1 /FEV 6 . The diagnostic accuracy of the questionnaires in discriminating between subjects with and without COPD (as summarised by the ROCAUC value) was 0.72 (95% CI 0.64, 0.79) for the CDQ score and 0.66 (95% CI 0.54, 0.77) for the DDQ score (Figure 4) . Although the lower cut-off point provided high sensitivity and NPV in the CF group, neither cut-off provided high specificity or PPV for either group (see Table 3 ). The PPV estimates for both questionnaires at either cutoff point were relatively low (between 36% and 44%) because of the high proportion of subjects without COPD who recorded scores in the 'increased' and 'intermediate' risk zones (false positives). Estimates of NPV were considerably higher owing to the low number of subjects with COPD scoring false negative values (< cut-off point 2; Table 3 ). The effect of adjustment for clustering depended on the size and sign of the estimated intracluster variation and was much more variable within the DD group (data not shown). The level of agreement between the classification of subjects based on the PiKo-6 ® FEV1/FEV6 cut-off ratio < 0.75 and the questionnaire scores at cut-off point 1 was fair (kappa overall = 0.22, kappa CF group = 0.21, kappa DD group = 0.23).
Discussion
To our knowledge, this is the first validation study of the diagnostic accuracy of a simple, hand-held, expiratory flow 
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PRIMARY CARE RESPIRATORY JOURNAL www.thepcrj.org meter (in this case the PiKo-6 ® ) using FEV1/FEV6 in a primary care setting. The ROCAUC showed a strong correlation between the pre-BD FEV 1/FEV6 measured using the flow meter and the reference diagnosis of COPD (a post-BD FEV 1/FEV of < 0.7). Equally high ROCAUC values were obtained in current and former smokers aged > 50 years old with no previous respiratory diagnosis (CF group; ROCAUC = 0.85) or previous asthma diagnosis (DD group; ROCAUC = 0.88). These values exceeded the ROCAUC estimates obtained in each group using COPD diagnostic questionnaires. Results indicated that the PiKo-6 ® is a simple and reliable screening tool that could facilitate early identification of airflow limitation.
Although office spirometry has been widely promoted, 12, 24 cost and benefit analysis does not support routine spirometric screening in primary care settings. 31 Significant barriers to spirometry in primary care include equipment and training costs, low reimbursement, low confidence with use and interpretation of results, perceived lack of utility, and quality assurance issues. 
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* Data unadjusted for clustering; Cut-off points as described by Price and co-workers. 23 Estimates are shown with 95% confidence limits in parentheses. Table 3 . Diagnostic accuracy of the COPD Diagnostic Questionnaires at different cut-off points.*
A key finding from this study was that despite the brief training provided to health care workers, a low-cost expiratory flow meter had remarkably high accuracy and reliability in the detection of airflow limitation. These findings suggest that simple, low-cost flow meters that require minimal training, such as the PiKo-6 ® , could facilitate the identification of patients who are likely to benefit from quality-assured spirometric evaluation.
Six-second expiratory manoeuvres offer several advantages over measurements of FVC in the elderly and in primary care. 24, 25, 32 Although concerns have been raised in relation to sensitivity 33, 34 and specificity 35 of spirometric FEV1/FEV6 for diagnosing airways obstruction, our findings show that this parameter may be a useful screening tool for COPD in at-risk primary care populations. Previous findings have suggested that the PiKo-6 ® with a high cut-off point (FEV1/FEV6 < 0.80) may improve detection of airflow limitation in primary care settings. 26 However, this cut-off point was based on personal experience of the authors and was selected to maximise specificity, albeit with a high rate of false-positive findings. The proposed cut-off point (FEV 1 /FEV 6 < 0.75) in our study was derived using standard validation statistics and identified patient groups with a high 'pre-spirometry likelihood' of COPD. The PPVs from our study suggest that about one out of every two patients who record a value below this cut-off point will exhibit a post-BD FEV 1/FEV of < 0.7 with spirometry. We would regard this as an efficient use of diagnostic resources. Following referral, diagnostic spirometry could be conducted within the primary care practice, an intermediate or community facility 20, 36 or specialist lung function laboratory. Conversely, the NPV estimates provide practitioners with a high degree of confidence that most (nine out of ten) patients who record a FEV 1/FEV6 > 0.75 with the PiKo-6 ® used in this study, do not have COPD. The proposed flow meter cut-off point is similar to the spirometry FEV 1/FEV6 cut-off point (< 0.73), which was previously shown to be a valid alternative to FEV 1/FVC < 0.70 as a fixed cut-off point for the diagnosis of airway obstruction. 37, 38 Estimates of the prevalence of COPD in the general population vary from 5-21% of adults in developed countries. 39 However, in this study, we assessed COPD in a selected population comprising adults attending primary care practices. Therefore, the prevalence of COPD in the CF and DD groups was higher than the prevalence of COPD that has been estimated from more general populations. The prevalence of spirometryconfirmed COPD in the CF (28%) and DD (39%) groups in this study was similar to findings from equivalent populations in the UK (CF = 21.9%, DD = 45%) and the US (CF = 16.0%, DD = 36%). 22, 28 In our study, the diagnostic accuracy of the COPD diagnostic questionnaires was different from Price and co-workers, who reported ROCAUC values of 0.82 and 0.84 for the CDQ and DDQ, respectively. 22, 23, 28 The reasons for this discrepancy in performance are not readily apparent. There were slight differences in the demographics of the study populations (the original study groups were, on average, slightly younger and had lower cumulative cigarette consumption). However, a more plausible explanation is that the COPD diagnostic questionnaires are of limited utility outside the development and validation populations. A recent external validation study found the CDQ to be a poor discriminator of those with and without COPD in a population of current smokers (ROCAUC = 0.65). 40 As in our study, specificity values were considerably lower than those reported by Price and co-workers. 23 In the present study, subjects were representative of individuals likely to be screened for COPD in primary care practices. Although the study diagnosis was made on the basis of spirometry at one visit and was not conducted in a lung function laboratory, the spirometers were calibrated, the operators were trained and blinded to previous test results, and the quality of spirometry was monitored. As there was no warning to withhold bronchodilator medication, there is a possibility that the 'no objective obstructive lung disease group' included subjects with well-controlled or inactive asthma, subjects with only minor obstructive changes, or subjects with asthma who had taken their bronchodilator before the visit. 41 Withholding of medication was not enforced because the study aimed to approximate the 'real-life' use of the device for 41 More studies in specialist lung function laboratories and randomised enrolment of patients would be required to confirm the findings from this study.
This is the first validation study to determine the diagnostic accuracy of an easy-use expiratory flow meter in a primary care setting. Similar to spirometry, the PiKo-6 ® requires full patient cooperation, but training for both the operator and the patient is straightforward. Given the findings from this study, the PiKo-6 ® should provide health care workers with a simple, reliable and practical method for targeted screening of patients at high risk of COPD. The simplicity and reliability of this case-finding tool, and the importance of COPD in adults, means that the PiKo-6 ® could fit into the busy work schedule of a primary care practitioner, alongside screening for hypertension. Further, using FEV 1/FEV6 from a simple flow meter could optimise early referral for spirometry and improve provision of early, targeted interventions aimed at reducing the burden of COPD.
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